Litcius/Paper detail

Daily phytate intake increases adiponectin levels among patients with diabetes type 2: a randomized crossover trial

Pilar Sanchís, Paula Calvó, Antelm Pujol, Rosmeri Rivera, Francisco Berga, Regina Fortuny, Antonia Costa‐Bauzá, F. Gráses, Luís Masmiquel

2023Nutrition and Diabetes24 citationsDOIOpen Access PDF

Abstract

AIM: Adiponectin, a major adipokine secreted by adipose tissue, has been shown to improve insulin sensitivity. Myo-inositol hexaphosphate (phytate; InsP6) is a natural compound that is abundant in cereals, legumes, and nuts that has demonstrated to have different beneficial properties in patients with diabetes type 2. METHODS: We performed a randomized crossover trial to investigate the impact of daily consumption of InsP6 on serum levels of adiponectin, TNF-alpha, IL-6, and IL-1beta in patients with type 2 diabetes mellitus (T2DM; n = 39). Thus, we measure serum levels of these inflammatory markers, classic vascular risk factors, and urinary InsP6 at baseline and at the end of the intervention period. RESULTS: Patients who consumed InsP6 supplements for 3 months had higher levels of adiponectin and lower HbA1c than those who did not consume InsP6. No differences were found in TNF-alpha, IL-6, and IL-1beta. CONCLUSION: This is the first report to show that consumption of InsP6 increases plasma adiponectin concentration in patients with T2DM. Consequently, our findings indicate that following a phytate-rich diet has beneficial effects on adiponectin and HbA1c concentrations and it could help to prevent or minimize diabetic-related complications.

Topics & Concepts

AdiponectinCrossover studyAdipokineType 2 diabetesMedicineInternal medicineEndocrinologyDiabetes mellitusRandomized controlled trialType 2 Diabetes MellitusInsulin resistancePlaceboAlternative medicinePathologyPhytase and its ApplicationsFood composition and propertiesAdipokines, Inflammation, and Metabolic Diseases
Daily phytate intake increases adiponectin levels among patients with diabetes type 2: a randomized crossover trial | Litcius